资讯

腾讯网9 天
EGFR-TKI 耐药后 MET 扩增检测：从「金标准」到精准优化，破解临床困境
近年来，随着表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKI）在非小细胞肺癌（NSCLC）中的广泛应用，耐药问题逐渐成为临床痛点。 2025 年美国临床肿瘤学会（ASCO）年会中，SACHI 研究公布更新数据，在 EGFR-TKIs ...
CURE2 天
FDA Approves Datroway for EGFR-Mutated Advanced Lung Cancer
Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and ...
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...
pharmaphorum1 天
AZ, Daiichi get Datroway nod in lung cancer on second try
AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval ...
Managed Healthcare Executive5 天
Lurbinectedin and Atezolizumab Combo Improves Survival in Extensive-Stage Small-Cell Lung ...
When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies ...
Fierce Pharma1 天
AZ, Daiichi's Datroway scores its 2nd FDA approval—this time in lung cancer subset
The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated ...
DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have ...
Everyday Health1 天
What Is Small Cell Lung Cancer (SCLC)?
Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.
DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with ...
DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non ...